Alzamend Neuro (ALZN) Fundamentals 2026 — Revenue Analysis | SniperIQ

.33 on the NASDAQ. This SniperIQ fundamentals page covers Alzamend Neuro's valuation, profitability (net margin 0.0%), balance-sheet quality, and AI signal context — from live market data, research only.

Full research coverage

• 8-Quarter Revenue & Margin Trend
• Debt Maturity & Coverage
• Peer Valuation Comparison
• Free Cash Flow & Owner Earnings
• AI Signal + Institutional Flow
• DCF Valuation Model

Frequently Asked Questions

What is Alzamend Neuro's market cap?

Alzamend Neuro (ALZN) has a market capitalization of approximately $4M, trading at

.33 on the NASDAQ. Market cap moves with the live share price.

What is Alzamend Neuro's P/E ratio?

Alzamend Neuro's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 2.3x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is Alzamend Neuro?

Alzamend Neuro runs a net profit margin of 0.0%, a gross margin of 0.0%, and an operating margin of 0.0%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

Does Alzamend Neuro pay a dividend?

Alzamend Neuro does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.

Is Alzamend Neuro financially healthy?

Alzamend Neuro carries a debt-to-equity ratio of 0.00x and a current ratio of 1.99x, with a market beta of 0.14. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is Alzamend Neuro a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Alzamend Neuro (ALZN) the key facts are: market cap $4M, 52-week range 0.84-3.139. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.